"Until now, drug switching between JAK inhibitors has not been reimbursed, so there have been unmet patient needs for rheumatoid arthritis patients who do not benefit from conventional biological agents. As reimbursement for drug switching will be granted starting in December, patients will be less burdened by switching from biological agents to JAK inhibitors. Also, patients will no longer resort to treatments they do not benefit from. The reimbursement approval will significantly change the treatment landscape for rheumatoid arthritis."

Dr. Seung-Jae Hong, a Professor in the Department of Rheumatology at Kyung Hee University Medical Center, remarked on changes to the treatment landscape for rheumatoi